OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
Andrew Blumenfeld, Kerry Knievel, Aubrey Manack Adams, et al.
Advances in Therapy (2021) Vol. 39, Iss. 1, pp. 692-705
Open Access | Times Cited: 9
Andrew Blumenfeld, Kerry Knievel, Aubrey Manack Adams, et al.
Advances in Therapy (2021) Vol. 39, Iss. 1, pp. 692-705
Open Access | Times Cited: 9
Showing 9 citing articles:
New Oral Drugs for Migraine
Nazia Karsan, Peter J. Goadsby
CNS Drugs (2022) Vol. 36, Iss. 9, pp. 933-949
Open Access | Times Cited: 19
Nazia Karsan, Peter J. Goadsby
CNS Drugs (2022) Vol. 36, Iss. 9, pp. 933-949
Open Access | Times Cited: 19
CGRP receptor antagonists (gepants)
Samaira Younis, Н. В. Латышева, A B Danilov, et al.
Handbook of clinical neurology (2024), pp. 51-66
Closed Access | Times Cited: 4
Samaira Younis, Н. В. Латышева, A B Danilov, et al.
Handbook of clinical neurology (2024), pp. 51-66
Closed Access | Times Cited: 4
A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine
Andreas A. Argyriou, Elisa Mantovani, Dimos D. Mitsikostas, et al.
Expert Review of Neurotherapeutics (2022) Vol. 22, Iss. 6, pp. 469-488
Closed Access | Times Cited: 18
Andreas A. Argyriou, Elisa Mantovani, Dimos D. Mitsikostas, et al.
Expert Review of Neurotherapeutics (2022) Vol. 22, Iss. 6, pp. 469-488
Closed Access | Times Cited: 18
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Ubrogepant: Mechanism of action, clinical and translational science
Ramesh Boinpally, Mohamad Shebley, Joel M. Trugman
Clinical and Translational Science (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 3
Ramesh Boinpally, Mohamad Shebley, Joel M. Trugman
Clinical and Translational Science (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 3
A Case of Acute Migraine Without Aura Treated With a New FDA-Approved Medication Ubrogepant
Maria A Shamsi, Mohammad Khalid
Cureus (2024)
Open Access
Maria A Shamsi, Mohammad Khalid
Cureus (2024)
Open Access
Seguridad cardiovascular de los nuevos fármacos para el tratamiento agudo y preventivo de la migraña: gepantes y ditanes
A Pérez-Rodríguez, P Bandrés-Hernández, C Anciones, et al.
Revista de Neurología (2023) Vol. 76, Iss. 09, pp. 295-295
Open Access
A Pérez-Rodríguez, P Bandrés-Hernández, C Anciones, et al.
Revista de Neurología (2023) Vol. 76, Iss. 09, pp. 295-295
Open Access
Acute Treatments for Episodic Migraine: Surveillance Report 2
Juliana H. Vande Pluym, Rashmi B. Halker Singh, Magdoleen H. Farah, et al.
(2022)
Open Access
Juliana H. Vande Pluym, Rashmi B. Halker Singh, Magdoleen H. Farah, et al.
(2022)
Open Access
